



Press release

5th World Congress of WUWHS:

APR presents the latest clinical outcomes on the management of leg ulcers with Nexodyn®

Balerna (Switzerland), 26th September 2016 - **Applied Pharma Research APR sa**, the Swiss independent developer of science driven and patent protected healthcare products, announces today at the **5th Congress of World Union of Wound Healing Societies**, held in Florence (Italy), the results of a clinical pilot study on the efficacy and safety of **Nexodyn®**, an innovative active cleanser for an optimized **wound care**.

Conducted by Prof. Robert Strohal, from the Federal Academic Teaching Hospital of Feldkirch (Austria), the study engaged 30 patients with critically colonized and locally infected leg ulcers over a period of 5 weeks. The treatment with Nexodyn®, establishing an active interaction with the **Wound Microenvironment**, has been associated with a **successful contribution of the control of local infection, reduction of bioburden and significant decrease of wound pH**, all supporting the promotion of chronic wound healing as expressed by a significant mean wound size reduction and 37% of fully healed wounds. The study also evaluated the **safety and tolerability of the treatment** including Nexodyn®, showing a favorable profile with no adverse events reported and high levels of relief and comfort at application. The results of this study are available at the poster session. The authors concluded that the acid-oxidizing solution Nexodyn® is a **highly tolerable and safe** medical device and it **successfully contributes** to healing in patients with chronic leg ulcers.

APR and **Angelini** - leading producer and marketer of pharmaceutical and healthcare products - signed a strategic partnership to commercialize Nexodyn® in the Italian market, under their own brand. In the occasion of the WUWHS Congress, the two companies cosponsor the satellite symposium **“Revisiting Wound cleansing: Modulation of Wound Microenvironment”** where **international opinion leaders** will discuss the role of Wound Microenvironment modulation and how an active wound cleanser may contribute to wound management and healing. The importance of reestablishing the conditions that sustain the physiological healing in the **Wound Microenvironment** with a product able to preserve cell viability and very comfortable at application will also be presented. Clinical data will be shown to reinforce the product’s benefits in clinical practice.

About Nexodyn®

Nexodyn® is an acidOxidizing spray solution, characterized by pH<3, RedOx >1000mV and stabilized Hypochlorous Acid (>95% of free chlorine species) - intended for use in the debridement, irrigation and moistening of acute and chronic wounds, ulcers, cuts, abrasions, burns and other lesions.

Nexodyn® has been developed based on APR's proprietary and patented technology TEHCLO® enabling the production of super-oxidized solutions containing free chlorine species, of which stabilized Hypochlorous Acid (HClO) in very high concentration (> 95%). A wide array of non-clinical experiments and clinical observations suggest Nexodyn® to act as a valid support to the activation of the physiological processes that restart wound healing, in presence of a favorable safety and tolerability profile.

The convenient and easy-to-use spray formulation completes Nexodyn's profile, providing healthcare professionals with a new tool for an optimized wound care.

About APR Applied Pharma Research s.a.

APR is a Swiss, independent developer of science driven, patent protected Healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in selected therapeutical areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.

For press releases and other company information visit: www.apr.ch

Contacts:

APR Applied Pharma Research s.a.,

Paolo Galfetti; CEO

T: +41 91 6957020 or email to paolo.galfetti@apr.ch

Havas PR Milan - Press Office

Sara Bernabovi

T: +39 02 85457032 or email to sara.bernabovi@havaspr.com